Browsing Tag
osimertinib
3 posts
Can J&J’s five-minute NSCLC injection disrupt the EGFR frontline market long ruled by osimertinib?
Johnson & Johnson’s five-minute NSCLC injection RYBREVANT FASPRO wins FDA approval. Learn how this subcutaneous delivery could reshape EGFR frontline therapy.
Genprex begins dosing of phase 1/2 trial of REQORSA, Tagrisso combo
Genprex has dosed the first patient in the Acclaim-1 phase 1/2 clinical trial of REQORSA immunogene therapy candidate…
AstraZeneca wins FDA approval for Tagrisso in adjuvant treatment of early-stage NSCLC patients with EGFR mutations
Find out how AstraZeneca’s expanded FDA approval for Tagrisso is transforming early-stage lung cancer treatment standards.